ETON
Eton Pharmaceuticals Inc
59.50$
+7.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.1% | +8.9% | +13.9% | +13.8% | +12.8% | +48.4% | +9.5% | +18.7% | -5.2% | +14.0% | +54.9% | – | |
| – | +40.3% | -19.7% | +16.5% | +16.6% | +28.6% | +43.5% | -5.6% | +108.5% | -44.0% | +16.5% | +27.8% | – | |
| – | -17.6% | +37.9% | +12.4% | +12.0% | +2.8% | +52.3% | +20.9% | -34.1% | +66.8% | +12.5% | +72.5% | – | |
| – | +70.2% | -37.8% | +356.2% | -83.0% | +72.5% | +33.3% | +219.7% | -70.0% | +60.1% | +5.3% | -47.0% | – | |
| – | +5.5% | +12.7% | +8.4% | -5.4% | +27.0% | +36.5% | +5.6% | -16.3% | +9.3% | +18.0% | +11.3% | – | |
| – | +13.6% | +3.3% | +47.4% | -32.3% | +0.9% | +76.7% | +29.7% | -31.2% | +15.4% | +15.8% | +2.4% | – | |
| – | – | – | – | – | +23.6% | -174.7% | – | – | – | -2.0% | +430.0% | – | |
| – | +1,064.5% | -97.0% | +372.7% | -84.6% | +16,562.5% | -12.8% | +3.0% | +1.2% | -0.3% | -30.5% | +28.1% | – | |
| – | – | – | – | – | -202.0% | – | – | – | – | +11.3% | +644.5% | – | |
| – | +2.2% | -15.5% | -74.1% | -333.3% | – | -14.9% | -10.8% | -142.4% | – | – | +600.0% | – | |
| – | – | – | – | – | -195.4% | – | – | – | – | +4.8% | +645.0% | – | |
| – | – | – | – | – | -119.8% | – | -146.6% | – | +1,268.0% | -48.7% | +586.0% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.